Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives

por Yang, Jingyan, Liu, Rongzhe, Ektare, Varun, Stephens, Jennifer, Shelbaya, Ahmed
Publicado en Appl Health Econ Health Policy (2021)

Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus

por Lopez, Janice M.S., Macomson, Brian, Ektare, Varun, Patel, Dipen, Botteman, Marc
Publicado en Am Health Drug Benefits (2015)

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patie...

por Aletaha, Daniel, Snedecor, Sonya J, Ektare, Varun, Xue, Mei, Bao, Yanjun, Garg, Vishvas
Publicado en Clinicoecon Outcomes Res (2017)